2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2008
An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials
Wijeysundera HC, You JJ, Nallamothu BK, Krumholz HM, Cantor WJ, Ko DT. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials. American Heart Journal 2008, 156: 564-572.e2. PMID: 18760142, DOI: 10.1016/j.ahj.2008.04.024.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryCardiac CatheterizationElectrocardiographyFemaleFibrinolytic AgentsHemorrhageHumansInjections, IntravenousInpatientsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaMyocardial ReperfusionRandomized Controlled Trials as TopicRecurrenceStentsStrokeThrombolytic TherapyConceptsST-segment elevation myocardial infarctionEarly invasive strategyPercutaneous coronary interventionElevation myocardial infarctionFibrinolytic therapyInvasive strategyMajor bleedingSTEMI patientsMyocardial infarctionHospital major bleedingIntravenous fibrinolytic therapyLarge randomized trialsRisk of strokeSignificant reductionCause mortalityEligible trialsCoronary interventionRandomized trialsContemporary trialsStent useInclusion criteriaPatientsReinfarctionTherapyTrials